Abstract
Despite the widespread distribution of Hepatitis B virus (HBV) infection and the ongoing controversy about HBV immunization, surprisingly few published studies examined in detail the economic impact of HBV infection in Europe. Therefore, we investigated a cohort of 180 patients throughout Germany to evaluate the economic burden of HBV-associated disease. In 58 patients with acute and 122 patients with chronic HBV infection, cost-consuming events including direct medical costs and work-loss costs were documented. The direct costs were DM 7702 (95% confidence interval (CI): 5473–9931) for each acute HBV infection and DM 4247 (CI: 1601–6893) per patient-year of chronic HBV infection, with marked differences between different stages of HBV disease. The derived overall costs (1997 price levels) per year were DM 10,018 (CI: 7613–12,421) and DM 4860 (CI: 2185–7536), respectively. Based on crude population-based estimates (30,000 acute and 420,000 chronic HBV cases), we calculated the total HBV-related costs in Germany to exceed DM 1200 millions in 1997 (CI: 924.2–1536.7), with the treatment of patients with chronic active HBV disease as the major cost determinant. Previously published data from Germany probably overestimated the financial impact of acute HBV infection. In summary, our results illustrate the ongoing economic importance of this potentially life-threatening, but preventable disease and support the call for more accurate HBV surveillance and control in Germany.
Similar content being viewed by others
References
Arnot R. The evolving efforts to control hepatitis B virus. Pediatr Infect Dis J 1998; 17 (7 Suppl): S26-S29.
Brechot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular car-cinomas in Europe. J Hepatol 1998; 29(2): 173–183.
Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337(24): 1733–1745.
Goudeau A. Epidemiology and eradication strategy for hepatitis B in Europe. European Regional Study Group. Vaccine 1990; 8 (Suppl): S113-S116.
Iwarson S, Jilg W, Stroffolini T. Substantial decline of notified hepatitis B in major parts of Europe after 1985. Scand J Infect Dis 1994; 26(1): 19–22.
Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol Belg 1998; 61(2): 175–182.
Robert-Koch-Institut. Zur Situation bei ausgewählten meldepflichtigen Infektionserkrankungen im Jahr 1997. Teil 3: Virushepatitiden. Epidemiologisches Bulletin 1998; 13: 85–89.
Jefferson T, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 1994; 3(1): 25–37.
Mortimer PP, Miller E. Commentary: Antenatal screening and targeting should be sufficient in some countries. Br Med J 1997; 314(7086): 1036–1037.
Goldberg D, McMenamin J. The United Kingdom's hepatitis B immunisation strategy-Where now? Commun Dis Public Health 1998; 1(2): 79–83.
Struve J, Giesecke J. Cost of acute hepatitis B infection in Swedish adults. Scand J Infect Dis 1993; 25(6): 693–697.
Van Damme P, Tormans G, Beutels P, van Doorslaer E. Hepatitis B prevention in Europe: A preliminary economic evaluation. Vaccine 1995; 13(Suppl 1): S54-S57.
Szucs TD, Schramm W. Economic evaluation of medical therapy-Methodological principles. Zentralbl Chir 1995; 120(8): 577–583.
Fleiss JL. An introduction to applied probability. In: Fleiss JL (ed.), Statistical methods for rates and proportions. 2 ed. vol. 1. New York, Chichester, Brisbane, Toronto: John Wiley & Sons, 1981: 1–19.
Lahaye D, Strauss P, Baleux C, van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet 1987; 2(8556): 441–443.
Williams JR, Nokes DJ, Medley GF, Anderson RM. The transmission dynamics of hepatitis B in the UK: A mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 1996; 116(1): 71–89.
Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Br Med J 1997; 314(7086): 1033–1036.
Szucs TD, Smala A, Berger K, Windorfer A. Economic evaluation of various hepatitis B immunisation strate-gies in children and adolescents. Med Klin 1998; 93(8): 468–477.
Adler MW, Belsey EM, McCutchan JA, Mindel A. Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br Med J (Clin Res Ed) 1983; 286(6378): 1621–1624.
Rivera F, Lissen E, Vazquez R, et al. Cost-benefit analysis of a program for vaccination against hepatitis B in health personnel of a hospital. Med Clin (Barc) 1984; 83(15): 611–614.
Lange W, Masihi KN. Epidemiology and economic importance of hepatitis B in the Federal Republic of Germany. Postgrad Med J 1987; 63 (Suppl 2): 21–26.
Szucs TD, Muller EI, Berger K. Cost structure of hepatitis B infection. Fortschr Med 1997; 115(4): 47–48.
Hoffmann V, Richter GM, Funk H, Otto G, Kauffmann GW. Liver transplantation and diagnostic radiology: socioeconomic aspects. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996; 165(2): 113–117.
Deutsches Kuratorium für Organspende, Jahresbericht 1998. Bad Honnef, Germany.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harbarth, S., Szucs, T., Berger, K. et al. The economic burden of Hepatitis B in Germany. Eur J Epidemiol 16, 173–177 (2000). https://doi.org/10.1023/A:1007624415699
Issue Date:
DOI: https://doi.org/10.1023/A:1007624415699